| Literature DB >> 26165154 |
Max A Kruziki1, Sumit Bhatnagar1, Daniel R Woldring1, Vandon T Duong1, Benjamin J Hackel2.
Abstract
Small protein ligands can provide superior physiological distribution compared with antibodies, and improved stability, production, and specific conjugation. Systematic evaluation of the PDB identified a scaffold to push the limits of small size and robust evolution of stable, high-affinity ligands: 45-residue T7 phage gene 2 protein (Gp2) contains an α helix opposite a β sheet with two adjacent loops amenable to mutation. De novo ligand discovery from 10(8) mutants and directed evolution toward four targets yielded target-specific binders with affinities as strong as 200 ± 100 pM, Tms from 65 °C ± 3 °C to 80°C ± 1 °C, and retained activity after thermal denaturation. For cancer targeting, a Gp2 domain for epidermal growth factor receptor was evolved with 18 ± 8 nM affinity, receptor-specific binding, and high thermal stability with refolding. The efficiency of evolving new binding function and the size, affinity, specificity, and stability of evolved domains render Gp2 a uniquely effective ligand scaffold.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26165154 PMCID: PMC4536934 DOI: 10.1016/j.chembiol.2015.06.012
Source DB: PubMed Journal: Chem Biol ISSN: 1074-5521